Skip to main content
. 2023 Jun 1;6(8):e202301902. doi: 10.26508/lsa.202301902

Table 3.

Serum data of miR-33b+/+ mice treated with AMOs.

Diet NC GAN GAN GAN GAN
AMOs NEG NEG anti-miR-33a anti-miR-33b anti-miR-33a + b
TP (g/dl) 5.06 ± 0.10 5.24 ± 0.09 5.31 ± 0.15 5.30 ± 0.15 5.13 ± 0.06
ALB (g/dl) 3.33 ± 0.10 3.23 ± 0.08 3.21 ± 0.11 3.23 ± 0.06 3.02 ± 0.04
AST (IU/l) 102.0 ± 13.4 725.6 ± 157.3 *** 423.4 ± 42.1 243.8 ± 72.0 ## 260.4 ± 42.9 ##
ALT (IU/l) 67.7 ± 24.8 749.1 ± 215.0 ** 349.0 ± 53.1 234.1 ± 68.9 # 240.6 ± 46.8 #
ALP (IU/l) 314.5 ± 21.3 596.4 ± 63.19 ** 657.0 ± 57.7 357.3 ± 41.9 ## 370.1 ± 25.4 #
LDH (IU/l) 1,505 ± 49.8 4,181 ± 654.0 *** 2,777 ± 213.7 # 2007 ± 204.1 ### 1,493 ± 178.4 ###
ChE (IU/l) 34.7 ± 1.1 49.9 ± 2.7 *** 46.4 ± 1.2 35.7 ± 2.0 ### 38.3 ± 1.6 ###
T-BIL (mg/dl) 0.100 ± 0.006 0.402 ± 0.113 * 0.336 ± 0.086 0.076 ± 0.008 ## 0.070 ± 0.008 ##
TBA (μmol/l) 15.0 ± 9.17 83.5 ± 29.6 * 51.9 ± 14.0 6.0 ± 0.9 ## 4.6 ± 0.8 ##
Fe (μg/dl) 114.7 ± 9.3 192.4 ± 8.2 *** 195.1 ± 9.6 202.6 ± 11.8 177.4 ± 9.7
T-Cho (mg/dl) 63.8 ± 3.6 114.5 ± 9.8 ** 121.9 ± 12.6 186.2 ± 8.6 ### 166.5 ± 4.5 ##
LDL-C (mg/dl) 6.2 ± 0.3 17.9 ± 0.83 *** 17.1 ± 0.82 23.0 ± 1.5 # 18.2 ± 1.1
HDL-C (mg/dl) 44.3 ± 2.3 61.5 ± 7.5 65.1 ± 8.5 99.2 ± 3.5 ### 92.0 ± 2.0 ##
F-CHO (mg/dl) 7.8 ± 0.8 20.0 ± 0.9 * 26.4 ± 3.4 38.4 ± 3.3 ### 30.5 ± 1.6 #
TG (mg/dl) 24.2 ± 2.5 18.9 ± 1.2 18.1 ± 2.6 15.7 ± 1.9 9.5 ± 0.6 #
NEFA (μEq/l) 999.5 ± 65.5 1,036 ± 88.2 1,192 ± 69.6 1,065 ± 82.9 962.5 ± 41.0
CRE (mg/dl) 0.11 ± 0.010 0.12 ± 0.006 0.13 ± 0.007 0.13 ± 0.011 0.12 ± 0.007
BUN (mg/dl) 21.3 ± 1.09 23.4 ± 0.77 23.53 ± 1.12 23.7 ± 1.02 22.9 ± 0.54

Male miR-33b+/+ mice were fed NC or the GAN diet and injected with the indicated AMOs from the age of 8 wk for 12 wk. Values are the mean ± S.E.M., n = 6 for NC and n = 8–10 for the GAN diet each, one-way ANOVA with Turkey’s post hoc test. *P < 0.05, **P < 0.01, and ***P < 0.001, compared with NEG (NC diet). #P < 0.05, ##P < 0.01, and ###P < 0.001, compared with NEG (GAN diet).